Kenvue Inc. (NYSE:KVUE) Shares Bought by Keybank National Association OH

Keybank National Association OH boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 12.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,675,727 shares of the company's stock after purchasing an additional 517,666 shares during the quarter. Keybank National Association OH owned approximately 0.24% of Kenvue worth $99,827,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Huntington National Bank raised its holdings in shares of Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company's stock worth $96,000 after acquiring an additional 871 shares in the last quarter. ING Groep NV increased its stake in Kenvue by 23.6% in the third quarter. ING Groep NV now owns 3,576,616 shares of the company's stock worth $82,727,000 after purchasing an additional 681,954 shares during the period. Handelsbanken Fonder AB grew its position in shares of Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after buying an additional 21,222 shares in the last quarter. Alberta Investment Management Corp grew its position in shares of Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after buying an additional 109,700 shares in the last quarter. Finally, Longbow Finance SA boosted its position in Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after purchasing an additional 13,287 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

KVUE stock traded down $0.36 during trading on Tuesday, hitting $23.44. 15,368,134 shares of the company traded hands, compared to its average volume of 14,603,316. The stock's 50-day simple moving average is $21.54 and its 200 day simple moving average is $22.30. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $44.79 billion, a PE ratio of 44.22, a P/E/G ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KVUE. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group lowered their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Citigroup reduced their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Finally, Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $23.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.